terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· June 30, 2026

Kneat Files Management Information Circular in Connection with the Previously Announced Thoma Bravo Transaction

View original at globenewswire.com
Kneat Files Management Information Circular in Connection with the Previously Announced Thoma Bravo Transaction Proposed Transaction Provides Significant, Immediate, and Certain Value to Shareholders Proposed Transaction Result of Comprehensive, Multi-Month Strategic Review Process Led by an Independent and Qualified S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Our Board members and executives have all agreed to support the Proposed Transaction, believing that it represents the best outcome for the Company.

    60% confidence
  • The purchase price of C$6.50 per share exceeds Kneat's 52-week high closing price and represents a 40% premium to the May 8, 2026 closing price, and 57%, 61%, and 54% premiums to the 30-, 60- and 90-day VWAP as of May 8, 2026.

    60% confidence
  • The Board unanimously determined that the Proposed Transaction is in the best interests of shareholders and reflects an attractive value considering Kneat's risk-adjusted standalone opportunity.

    60% confidence
  • The Proposed Transaction values Kneat at an enterprise value of C$622 million, approximately 7.2x NTM revenue and approximately 9.3x LTM revenue, significantly higher than peers and precedent transactions.

    60% confidence
  • ARR growth has decelerated significantly from 51% in Q1 2025 to 20% in Q1 2026, and growth is increasingly dependent on uncertain large customer expansion.

    60% confidence
  • Competitive pressure is intensifying as established enterprise software vendors advance their own validation capabilities and actively solicit Kneat's customers, threatening its market share.

    60% confidence
  • The Kneat Board of Directors urges shareholders to vote FOR the Proposed Transaction today, believing it is in the best interests of the Company and its shareholders.

    60% confidence
  • Prior to the public announcement of the strategic review, Kneat's stock price had declined approximately 35% from its all-time high, sector valuation multiples had contracted, and analysts had reduced revenue and EBITDA estimates.

    60% confidence
  • The Special Committee reached out to 36 financial sponsors and 10 strategic buyers, of which 34 sponsors and 2 strategic buyers signed NDAs; management engaged 18 interested parties, 12 of which submitted indicative offers; negotiations resulted in a material increase to Thoma Bravo's bid.

    60% confidence
  • Kneat's customer base remains heavily concentrated, with the top 10 customers accounting for approximately 50% of revenue, exposing the Company to significant revenue volatility.

    60% confidence
  • The Board believes the proposed transaction with Thoma Bravo is in the best interests of the Company and maximizes value for shareholders.

    60% confidence
  • Ongoing investment in R&D, sales, and G&A mean Kneat is likely to remain unprofitable for the foreseeable future, limiting financial flexibility.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com